Aclaris' MK2 Inhibitor Shows Encouraging Data In Phase I
Zacks Investment Research | Jan 13, 2020 05:03AM ET
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) announced positive data from the phase I ATI-450-PKPD-101 study on it investigational MK2 inhibitor, ATI-450, currently being developed for addressing immuno-inflammatory diseases.
The single ascending dose and multiple ascending dose (SAD/MAD) clinical study evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered ATI-450 in healthy patients.
Preliminary data from the study showed that treatment with ATI-450 led to marked inhibition of key inflammatory cytokines, such as TNFα, IL1β, IL8, and IL6 and was generally well-tolerated across all-dose level tested. No serious side effects were reported from the same.
Importantly, preliminary data from the study supports progression to a phase IIa proof-of-concept studies for immuno-inflammatory diseases. Aclaris plans to initiate a phase II study for treating rheumatoid arthritis in the first half of this year.
Shares of Aclaris rallied 17.2% following this announcement. However, the stock has plunged 68.2% in the past year against the industry’s rise of 0.8%.
We remind investors that in October 2019, Aclaris sold the worldwide rights to its rosacea drug Rhofade Cream and certain licenses to its related intellectual property assets to privately-held, specialty pharmaceutical company EPI Health for $55 million. The divestiture is part of Aclaris’ ongoing restructuring program to focus on its immuno-inflammatory pipeline.
Notably, Aclaris acquired the rights to Rhofade from Allergan (NYSE:AGN) in 2018.
The company is currently developing its pipeline candidate, A-101 45% topical solution for the treatment of common warts in two late-stage studies. The candidate met the primary and all secondary efficacy endpoints, achieving clinically and statistically significant clearance of common warts in both phase III studies of THWART-1 and THWART-2.
This apart, Aclaris has two JAK inhibitors, namely ATI-501 and ATI-502 in mid-stage development for the treating alopecia. The company had in-licensed these two candidates from Rigel Pharmaceuticals, Inc, (NASDAQ:RIGL) in 2015. It has several other pre-clinical candidates in its portfolio.
Zacks Rank & Key Pick
Aclaris currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the same sector is Karyopharm Therapeutics Inc. (NASDAQ:KPTI) , sporting a Zacks Rank #1 (Strong Buy). You can see .
Get The News You Want
Karyopharm’s loss per share estimates have narrowed 0.5% for 2020 over the past 60 days. The stock has surged 89.6% in the past year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.